The cost-effectiveness of antithrombin replacement for thromboprophylaxis following asparaginase was recently evaluated in a single-center, retrospective study involving 92 individuals.

Investigators looked at 2 sets of antithrombin replacement thresholds and targets in adults receiving asparaginase-containing chemotherapy. Among the results:

• Cumulative thrombosis incidence was 16% at 6 months.
• Most thrombotic events occurred during induction chemotherapy and demonstrated no links with replacement target, cumulative days or cumulative area under antithrombin activity target, number of asparaginase doses, or cumulative asparaginase dose.
• Median estimated antithrombin replacement expenditure was ~$35,000 per patient.